Research programme: hepatitis C virus protease therapeutics - MetalloPharm
Latest Information Update: 04 Aug 2016
At a glance
- Originator MetalloPharm
- Class Antivirals
- Mechanism of Action Hepatitis C protease inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
- Available For Licensing Yes - Hepatitis C
Highest Development Phases
- Research Hepatitis C
Most Recent Events
- 04 Aug 2016 Research programme: hepatitis C virus protease therapeutics - MetalloPharm is available for licensing as of 04 Aug 2016. http://www.metallopharm.com/